Imugene begins manufacture of its innovative cancer vaccine for trials
Sunday, 23 September 2018 Imugene Limited (ASX:IMU) has formally commenced cGMP (current good manufacturing practice) manufacture of the clinical batch of its cancer vaccine KEY-Vaxx. The cGMP batch is part of the pre-clinical development for the proposed PD-1 phase I clinical trial to be conducted in 2019. AmbioPharm Inc, a US-based peptide manufacturing company has been appointed to manufacture the vaccine. We've commenced cGMP manufacturing of the clinical batch of cancer vaccine KEY-Vaxx for the proposed Phase 1 PD-1 clinical trial, after successfully completing pilot studies. AmbioPharm Inc. (APi), a US-based cGMP manufacturer has been appointed $IMU #ASX https://t.co/xL390CKopH pic.twitter.com/YVOYROEtbZ — Imugene Ltd (@TeamImugene) September 20, 2018 KEY-Vaxx is a B-cell peptide cancer vaccine which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and potentially produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming the treatment of a range of cancers. KEY-Vaxx has shown potential in preclinical studies, outperforming an industry-standard antibody in a mouse model of HER2+ colorectal cancer. New provisional patent The protection of Imugene’s global position in PD-1 B-cell cancer vaccines has been strengthened with the filing of a new provisional patent in Australia titled “A vaccine composition and uses thereof”. READ: Imugene signs exclusive, world-widelicence for cancer vaccine Imugene managing director Leslie Chong said: “Maintaining and strengthening our already strong international intellectual property position is a key area of focus in maintaining the competitive advantage of KEY-Vaxx and any future improvements, vaccine formulations and clinical uses. “We are extremely pleased with the progress made from our expert scientific team.”
Ever since it was introduced in 2013, CRISPR has been touted as a promising technology for treating inherited disorders, cancer, and other diseases with no current treatment options. Teams of researchers had been hoping to begin human trials in 2018, but none of those trials have taken place yet with...
According to UPI, those who like drinking hot tea might want to wait until it gets cooler before taking that first sip. Drinking more than 700ML of tea at higher than 140 degrees Fahrenheit, was linked..
Sitting in her living room, Kristi Card is knitting the knots of compassion all for some of cancer's tiniest fighters. The Littleton woman began knitting and selling scarves years ago after losing her..
Credit: 7News - The Denver Channel Duration: 02:20Published
Alex Trebek Returns to 'Jeopardy!' After Announcing Cancer Diagnosis The longtime host recently made a video announcement and revealed he has stage 4 pancreatic cancer. Only one week after announcing..